Apixaban Concentration with and without Coadministration of Carbamazepine: A Case with No Apparent Interaction.

about

Apixaban Concentration with and without Coadministration of Carbamazepine: A Case with No Apparent Interaction.

Item

http://www.wikidata.org/entity/Q49335499

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Apixaban Concentration with an ...... with No Apparent Interaction.

@en

Apixaban Concentration with an ...... with No Apparent Interaction.

@nl

type

Item

label

Apixaban Concentration with an ...... with No Apparent Interaction.

@en

Apixaban Concentration with an ...... with No Apparent Interaction.

@nl

prefLabel

Apixaban Concentration with an ...... with No Apparent Interaction.

@en

Apixaban Concentration with an ...... with No Apparent Interaction.

@nl

P1476

Apixaban Concentration with an ...... with No Apparent Interaction.

@en

P2093

Artur Szkotak

http://www.w3.org/2001/XMLSchema#string

Linda Stang

http://www.w3.org/2001/XMLSchema#string

Norelle Evanger

http://www.w3.org/2001/XMLSchema#string

Tammy J Bungard

http://www.w3.org/2001/XMLSchema#string

P2860

A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients

In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation

Direct oral anticoagulant drug level testing in clinical practice: A single institution experience.

Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.

Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.

Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?

Laboratory measurement of the direct oral anticoagulants.

P304

463-467

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.4212/CJHP.V70I6.1714

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29299007

http://www.w3.org/2001/XMLSchema#string

P932

5737190

http://www.w3.org/2001/XMLSchema#string